About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

CUTE (Chronic Urticaria Treatment Evaluation) | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 4NCT00264303

CUTE (Chronic Urticaria Treatment Evaluation)

A study to compare the clinical efficacy and safety of Levocetirizine vs. Desloratadine in patients suffering from Chronic Idiopathic Urticaria (CIU) measured by the mean pruritus severity score over ...

Lead sponsor: UCB Pharma•80 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

UCB Pharma

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•\- At visit 1: Clinical history of Chronic Idiopathic Urticaria for a period of at least 6 weeks during the last 3 months without an identifiable cause
•\- At visit 2 (after a baseline period of at least 3 days): patient with adequate signs of CIU, both in terms of symptoms and severity.

Exclusion Criteria

•\- Any condition that would interfere with the evaluation of the therapeutic response.

Related studies

Not Yet RecruitingPhase 3

Autologous Whole Blood Therapy in Chronic Idiopathic Urticaria Patients.

NCT07486583 · Chronic Idiopathic Urticaria

COMPLETEDPhase 2

Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria

NCT05936567 · Urticaria, Chronic Spontaneous Urticaria, and more

COMPLETEDPhase 2

A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases

NCT03858634 · Chronic Idiopathic Urticaria, Chronic Idiopathic Pruritus, and more

COMPLETEDPhase 3

Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria

NCT05774639 · Chronic Idiopathic Urticaria

COMPLETEDPhase 4

Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody

NCT03183024 · Chronic Idiopathic Urticaria

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: August 31, 2011Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE4

Enrollment886

Start dateDec 2005

Last updatedAug 31, 2011

Condition

Chronic Idiopathic Urticaria

Locations shown

Bruges

Brussels

Liège

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 31, 2011Data synced to Clareo: July 12, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions